С. difficile infection: clinical and pharmacoeconomic assessment of treatment regimens in antibiotic-associated diarrhea | CMAC

С. difficile infection: clinical and pharmacoeconomic assessment of treatment regimens in antibiotic-associated diarrhea

Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):303-307

​ Ortenberg E.A.
10.36488/cmac.2022.4.303-307
Clostridioides difficile antibiotic-associated diarrhea treatment vancomycin metronidazole teicoplanin costeffectiveness
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(4):303-307

Abstract

This paper provides a review of the largest studies (over the period of 2017 to 2022) on cost-effectiveness analysis of the recommended treatment algorithms for Clostridioides difficile infection in patients with antibiotic-associated diarrhea (AAD), including pseudomembranous colitis. The review showed that professional medical societies in Russia, EU and US as well as meta-analyses consistently consider vancomycin as the most important treatment option for AAD and pseudomembranous colitis. The role of metronidazole and fidaxomicin in the treatment of AAD is considered ambiguous. Teicoplanin is recommended for using more commonly based on cost-effectiveness analysis.

Eduard A. Ortenberg

Tyumen State Medical University, Tyumen, Russia

  • 1. Fettucciari K., Marconi P., Marchegiani A., Fruganti A., Spaterna A., Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Therap Adv Gastroenterol. 2021;14:175628482 11032797. DOI: 10.1177/17562848211032797
  • 2. Guh A.Y., Preeta K. Kutty P.K. Clostridioides difficile infection. Ann Intern Med. 2018;169(7):TC49-ITC64. DOI: 10.7326/AITC201810020
  • 3. Debast S.B., Bauer M. P., Kuijper E.J. on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl. 2):1-26. DOI: 10.1111/14690691.12418
  • 4. Ivashkin V.T., Yushchuk N.D., Mayev I.V., Lapina T.L., Poluektova Y.A., Shifrin O.S., et al. Diagnostics and treatment of Clostridium difficile-associated disease: guidelines of the Russian gastroenterological association. Russian journal of gastroenterology, hepatology, coloproctology. 2016;26(5):56-65. Russian. DOI: 10.22416/1382-4376-201626-5-56-65
  • 5. Shelygin Yu.A., Aleshkin V.A., Sukhina M.A., Mironov A.Yu., Briko N.I., Kozlov R.S., et al. Clinical recommendations of the national association of specialists for the healthcare-related infections control and the Russian association of coloproctology on diagnosis, treatment and prophylaxis of Clostridium difficile-associated diarrhea (CDI). Coloproctology. 2018;(3):7-23. Russian. DOI: 10.33878/2073-7556-2018-0-3-7-23
  • 6. Abreu Y Abreu A.T., Velarde-Ruiz Velasco J.A., ZavalaSolares M.R., Remes-Troche J.M., Carmona-Sánchez R.I., Aldana-Ledesma J.M., et al. Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed). 2019;84(2):204-219. DOI: 10.1016/j.rgmx.2018.12.001
  • 7. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. DOI: 10.1093/cid/cix1085
  • 8. Britton R.A., Vincent B., Young V.B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012;20(7):313319. DOI: 10.1016/j.tim.2012.04.001
  • 9. Lyerly D.M., Krivan H.C., Wilkins T.D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988;1(1):118. DOI: 10.1128/cmr.1.1.1
  • 10. Jarmo O., Veli-Jukka A., Eero M. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med. 2020;52(12):12-20. DOI: 10.1080/07853890.2019.1701703
  • 11. Wang Y., Ye Z., Ge L., Siemieniuk R.A.C., Wang X., Wang Y., et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ. 2020;368:l6744. DOI: 10.1136/bmj.l6744
  • 12. Nelson R.L., Suda K.J., Evans C.T. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3(3):CD004610. DOI: 10.1002/14651858.CD004610.pub5
  • 13. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-431. DOI: 10.1056/NEJMoa0910812
  • 14. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289. DOI: 10.1016/S1473-3099(11)70374-7
  • 15. Dilnessa T., Getaneh A., Hailu W., Moges F., Gelaw B. Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: a systematic review and meta-analysis. PLoS One. 2022;17(1):e0262597. DOI: 10.1371/journal.pone.0262597
  • 16. Okumura H., Fukushima A., Taieb V., Shoji S., English M. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis. J Infect Chemother. 2020;26(1):43-50. DOI: 10.1016/j.jiac.2019.07.005
  • 17. Wolf J., Kalocsai K., Fortuny C., Lazar S., Bosis S., Korczowski B., et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis. 2020;71(10):2581-2588. DOI: 10.1093/cid/ciz1149
  • 18. Guery B., Menichetti F., Anttila V-J., Adomakoh N., Aguado J.M., Bisnauthsing K., et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018;18(3):296-307. DOI: 10.1016/S1473-3099(17)30751-X
  • 19. Clostridioides difficile infection: antimicrobial prescribing. NICE Guideline, No. 199. National Institute for Health and Care Excellence (NICE). July 23, 2021.
  • 20. Adelman M.W., Woodworth M.H., Shaffer V.O., Martin G.S., Kraft C.S. Critical care management of the patient with Clostridioides difficile. Crit Care Med. 2021;49(1): 127-139. DOI: 10.1097/CCM.0000000000004739
  • 21. Tariq R., Laguio-Vila M., Tahir M.W., Orenstein R., Pardi D.S., Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:1756284821994046. DOI: 10.1177/1756284821994046
  • 22. Maraolo A.E., Mazzitelli M., Zappulo E., Scotto R., Granata G., Andini R., et al. Oral vancomycin prophylaxis for primary and secondary prevention of Clostridioides difficile infection in patients treated with systemic antibiotic therapy: a systematic review, meta-analysis and trial sequential analysis. Antibiotics (Basel). 2022;11(2):183. DOI: 10.3390/antibiotics11020183
  • 23. Lalla F., Santoro D., Rinaldi E., Suter F., Cruciani M., Guaglianone M.H., et al. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria. J Antimicrob Chemother. 1989;23(1):131-142. DOI: 10.1093/jac/23.1.131
  • 24. Ojha S.C., Phanchana M., Harnvoravongchai P., Chankhamhaengdecha S., Singhakaew S., Ounjai P., Janvilisri T. Teicoplanin suppresses vegetative Clostridioides difficile and spore outgrowth. Antibiotics (Basel). 2021;10(8):984. DOI: 10.3390/antibiotics10080984
  • 25. Beinortas T., Burr N.E., Wilcox M.H., Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network metaanalysis. Lancet Infect Dis. 2018;18(9):1035-1044. DOI: 10.1016/S1473-3099(18)30285-8
  • 26. Le P., Nghiem V.T., Mullen P.D., Deshpande A. Costeffectiveness of competing treatment strategies for Clostridium difficile infection: a systematic review. Infect Control Hosp Epidemiol. 2018;39(4):412-424. DOI: 10.1017/ice.2017.303
  • 27. Gupta A., Ananthakrishnan A.N. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654. DOI: 10.1177/17562848211018654
Views
0 Abstract
0 PDF
0 Crossref citations
Shared